CYTOKINE & GROWTH FACTOR REVIEWS

metrics 2024

Navigating the Complexities of Endocrinology and Immunology

Introduction

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.

Metrics 2024

SCIMAGO Journal Rank2.46
Journal Impact Factor9.30
Journal Impact Factor (5 years)10.20
H-Index182
Journal IF Without Self9.30
Eigen Factor0.00
Normal Eigen Factor1.04
Influence2.17
Immediacy Index2.90
Cited Half Life8.40
Citing Half Life6.40
JCI1.34
Total Documents1199
WOS Total Citations7894
SCIMAGO Total Citations31619
SCIMAGO SELF Citations391
Scopus Journal Rank2.46
Cites / Document (2 Years)9.11
Cites / Document (3 Years)10.72
Cites / Document (4 Years)10.70

Metrics History

Rank 2024

Scopus

Endocrinology, Diabetes and Metabolism in Medicine
Rank #7/244
Percentile 97.13
Quartile Q1
General Biochemistry, Genetics and Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #9/221
Percentile 95.93
Quartile Q1
Immunology and Allergy in Medicine
Rank #16/233
Percentile 93.13
Quartile Q1
Immunology in Immunology and Microbiology
Rank #19/236
Percentile 91.95
Quartile Q1

IF (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 25/313
Percentile 92.20
Quartile Q1
CELL BIOLOGY
Rank 28/205
Percentile 86.60
Quartile Q1

JCI (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 40/313
Percentile 87.22
Quartile Q1
CELL BIOLOGY
Rank 35/205
Percentile 82.93
Quartile Q1

Quartile History

Similar Journals

CELL PROLIFERATION

Exploring Innovations in Cellular and Molecular Biology
Publisher: WILEYISSN: 0960-7722Frequency: 12 issues/year

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

JOURNAL OF MOLECULAR MEDICINE-JMM

Pioneering Insights in Drug Discovery and Genetics.
Publisher: SPRINGER HEIDELBERGISSN: 0946-2716Frequency: 12 issues/year

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

FEBS Journal

Where Innovation Meets Molecular Insights
Publisher: WILEYISSN: 1742-464XFrequency: 24 issues/year

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

Cell Death & Disease

Leading the charge in transformative biomedical discoveries.
Publisher: SPRINGERNATUREISSN: 2041-4889Frequency: 1 issue/year

Cell Death & Disease, published by SpringerNature, is a premier open-access journal dedicated to disseminating high-quality research on the mechanisms and implications of cell death, disease pathology, and therapeutic responses. Since its inception in 2010, the journal has quickly established itself within the top tier of academic publishing, achieving a notable impact factor and earning Q1 rankings in several critical categories including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, Immunology, and Medicine (miscellaneous). With its commitment to open access, Cell Death & Disease ensures that groundbreaking research is available to a global audience, fostering collaboration and advancing knowledge across disciplines. Residing at the forefront of crucial scientific discourse, this journal not only attracts submissions from leading researchers but also significantly influences the fields of molecular biology, immunology, and neurology. By bridging the gap between basic science and clinical applications, it provides vital insights for professionals, academicians, and students alike.

CYTOKINE

Elevating the discourse in cytokine research and application.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1043-4666Frequency: 12 issues/year

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.

BIOCELL

Pioneering Discoveries in Molecular Biology
Publisher: TECH SCIENCE PRESSISSN: 0327-9545Frequency: 12 issues/year

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Leading the Charge in Cancer Immunology Innovations
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Blood Cancer Discovery

Transforming Research into Life-Saving Solutions
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Cell Communication and Signaling

Exploring the Nuances of Molecular Signaling
Publisher: BMCISSN: Frequency: 1 issue/year

Cell Communication and Signaling is a premier peer-reviewed journal published by BMC that has made significant contributions to the fields of biochemistry, cell biology, and molecular biology since its establishment in 2003. As an open access journal, it offers unrestricted access to high-quality research, fostering collaboration and innovation among scientists around the globe. The journal is distinguished by its Q1 ranking in all three relevant categories for 2023, underscoring its critical role in advancing the understanding of cellular communication mechanisms and signaling pathways. Positioned within the United Kingdom, Cell Communication and Signaling has been an invaluable resource for researchers, professionals, and students alike, ensuring that the latest findings are accessible to a diverse range of audiences. With an impressive Scopus ranking—placing it in the top percentiles within its subject areas—this journal continues to set the standard for excellence in the pursuit of understanding complex cellular interactions.